½ÃÀ庸°í¼­
»óǰÄÚµå
1596769

±âÁú Ç÷°ü ºÐȹ ½ÃÀå : Á¦Ç°, ¿ëµµ ¹× ÃÖÁ¾ ¿ëµµº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Stromal Vascular Fraction Market by Product (Aspiration, Isolation, Transfer), Application (Cosmetic, Orthopedic, Soft Tissue), End-Use - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 192 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

±âÁú Ç÷°ü ºÐȹ ½ÃÀåÀº 2023³â¿¡ 3¾ï 7,144¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2024³â¿¡´Â 5¾ï 1,694¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 39.65%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 38¾ï 4,895¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù.

°£ÁúÇ÷°üºÐȹ(SVF)Àº °£¿±Áٱ⼼Æ÷, ³»ÇǼ¼Æ÷, ¸é¿ª¼¼Æ÷ µî dzºÎÇÑ Àç»ý¼¼Æ÷¸¦ Æ÷ÇÔÇÏ´Â Áö¹æÁ¶Á÷ À¯·¡ ¼¼Æ÷±ºÀ» ¸»Çϸç, SVFÀÇ ¹üÀ§´Â Àç»ýÀÇÇÐ, ¹Ì¿ë, ±×¸®°í ÀáÀçÀûÀ¸·Î ´Ù¾çÇÑ ÁúȯÀÇ Ä¡·á¿¡ Àû¿ëµÉ ¼ö ÀÖ´Â Áß¿äÇÑ ¿ªÇÒÀ» Æ÷ÇÔÇϰí ÀÖ½À´Ï´Ù. ¼¼Æ÷ ¼ººÐÀ¸·Î Ä¡À¯¿Í Á¶Á÷ Àç»ýÀ» ÃËÁøÇÏ´Â ´É·Â¿¡ ÀÖ½À´Ï´Ù. ƯÈ÷ Áö¹æ ÀÌ½Ä ¹× Á¶Á÷ Áõ°­À» À§ÇÑ ¹Ì¿ë ÀÇ·á, °üÀý Àç»ýÀ» ÃËÁøÇÏ´Â ¼ºÇü¿Ü°ú, ½É±Ù Àç»ý¿¡ À¯¸ÁÇÑ ½ÉÀ庴ÇÐ µî ´Ù¾çÇÑ ÀÀ¿ë ºÐ¾ß°¡ ÀÖ½À´Ï´Ù. ÃÖÁ¾ »ç¿ë ¹üÀ§´Â ÁÖ·Î ÀÇ·á ½Ã¼³, ¿¬±¸ ±â°ü, ¹Ì¿ë ¼ö¼ú¼¾ÅÍ¿¡ À̸£±â±îÁö ´Ù¾çÇÕ´Ï´Ù. ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀº ¸¸¼º Áúȯ ȯÀÚ Áõ°¡, ÀÇ·á ÀÎÇÁ¶óÀÇ ¹ßÀü, È¿À²ÀûÀ̰í ÃÖ¼Ò Ä§½ÀÀûÀÎ Ä¡·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ÀÔ´Ï´Ù. ÃÖ±Ù Ãß¼¼´Â ½Å°æ ÅðÇ༺ ÁúȯÀÇ Ä¡·á¹ý °³¹ß¿¡ SVF¸¦ Ȱ¿ëÇÏ°í »õ·Î¿î Ä¡·á ¿µ¿ªÀ¸·ÎÀÇ Àû¿ëÀ» È®´ëÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ±âȸ¸¦ Ȱ¿ëÇϱâ À§ÇÑ ¿¬±¸ ÁÖüµéÀº SVF¸¦ ÀÌ¿ëÇÑ »õ·Î¿î Ä¡·á¹ý ¿¬±¸¿¡ ´ëÇÑ ÅõÀÚ, ¹ÙÀÌ¿ÀÅ×Å© ±â¾÷°ú ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü¿ÍÀÇ Çù·Â °­È­, ½ÃÀå ÁøÀÔÀ» ¿ëÀÌÇÏ°Ô Çϱâ À§ÇÑ ±ÔÁ¦ Áؼö¿¡ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ ¿¬µµ(2023³â) 3¾ï 7,144¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2024³â) 5¾ï 1,694¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2030³â) 38¾ï 4,895¸¸ ´Þ·¯
CAGR(%) 39.65%

±×·¯³ª ¾ö°ÝÇÑ ¾ÈÀü ±âÁذú Áö¿ªº°·Î »óÀÌÇÑ ±ÔÁ¤ Áؼö ¿ä°ÇÀ¸·Î ÀÎÇÑ ±ÔÁ¦Àû Àå¾Ö¹°µµ ¿©ÀüÈ÷ ³²¾Æ ÀÖ½À´Ï´Ù. SVF ÃßÃâ ±â¼ú °³¼±, ¼¼Æ÷ Àü´Þ ¹× ÅëÇÕÀ» °­È­ÇÏ´Â Àΰø ½ºÄ³Æúµù Àç·áÀÇ Á¦Á¶, SVF ¼¼Æ÷ÀÇ º¸Á¸ ¹× ¿î¼Û ½Ã½ºÅÛ ÃÖÀûÈ­¿¡ ´ëÇÑ ¿¬±¸µµ SVF ¼¼Æ÷ÀÇ º¸Á¸ ¹× ¿î¼Û ½Ã½ºÅÛ ÃÖÀûÈ­¸¦ À§ÇÑ ±â¼ú Çõ½ÅÀÌ ¹«¸£À;°í ÀÖ½À´Ï´Ù. ¿¬±¸ ¶ÇÇÑ »ç¾÷ ¼ºÀåÀ» ¾à¼ÓÇϰí ÀÖ½À´Ï´Ù. ½ÃÀåÀº ¿ªµ¿ÀûÀÌ°í ºü¸¥ ±â¼ú ¹ßÀü°ú ÁøÈ­ÇÏ´Â ±ÔÁ¦ ȯ°æÀ¸·Î ÀÎÇØ ±â¾÷Àº ¼ºÀå°ú Çõ½ÅÀ» À¯ÁöÇϱâ À§ÇØ ¹ÎøÇϰí ÀûÀÀ·ÂÀ» À¯ÁöÇØ¾ß ÇÕ´Ï´Ù.

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â ±âÁú Ç÷°ü ºÐȹ ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ®¸¦ °ø°³ÇÕ´Ï´Ù.

±âÁú Ç÷°ü ºÐȹ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ º¯È­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤À» ³»¸®°í, Àü·«ÀûÀÎ ÀÇ»ç°áÁ¤À» Á¤±³È­Çϸç, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • Àç»ýÀÇ·á °ü·Ã ÀüÀÓ»ó ¹× ÀÓ»ó ¿¬±¸ Áõ°¡
    • °ñ°üÀý¿°, ¿¬°ñ Àç»ýÀ» Æ÷ÇÔÇÑ ´Ù¾çÇÑ Áúȯ¿¡ ´ëÇÑ ¼ö¼ú Áõ°¡
    • È­»ó ¹× ÇǺΠÁúȯ Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • SVF¿ë ¼ö¼ú±â±¸ÀÇ ³ôÀº ºñ¿ë
  • ½ÃÀå ±âȸ
    • SVF¿ë ½ÅÁ¦Ç° Ãâ½Ã¸¦ À§ÇÑ ±â¼ú Çõ½Å
    • Á¤¸ÆÁÖ»çÀÇ È¿°úÀûÀÎ °ü¸®¸¦ À§ÇÑ Áö¼ÓÀûÀÎ Àü·«Àû ÅõÀÚ
  • ½ÃÀå °úÁ¦
    • ¼÷·Ã°ø ºÎÁ· ¹× Á¦Ç° ¸®ÄÝ

Portre's Five Forces: ±âÁú Ç÷°ü ºÐȹ ½ÃÀåÀ» Ž»öÇÏ´Â Àü·«Àû µµ±¸

Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂû·ÂÀ» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : °£Áú¼º Ç÷°üºÐȹÁ¦Á¦ ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ±âÁú Ç÷°ü ºÐȹ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® °£Áú¼º Ç÷°üºÐȹÁ¦Á¦ ½ÃÀå¿¡¼­ÀÇ °æÀï»óȲ ÆÄ¾Ç

±âÁú Ç÷°ü ºÐȹ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü µî ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­, ÅëÇÕÀÇ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÅëÂû·ÂÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º ±âÁú Ç÷°ü ºÐȹ ½ÃÀå¿¡¼­ º¥´õÀÇ ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ±âÁú Ç÷°ü ºÐȹ ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ °£Áú¼º Ç÷°üºÐȹÁ¦Á¦ ½ÃÀå¿¡¼­ÀÇ ¼º°øÀ» À§ÇÑ Àü·« ºÐ¼® ¹× Ãßõ

±âÁú Ç÷°ü ºÐȹ ½ÃÀåÀÇ Àü·«Àû ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ȯ°æÀÇ µµÀüÀ» ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö ÀÖµµ·Ï ÁغñÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • PorterÀÇ Five Forces ºÐ¼®
  • PESTLE ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå ±âÁú Ç÷°ü ºÐȹ ½ÃÀå : Á¦Ç°º°

  • ¼Ò¸Á
  • ºÐ¸®
  • À̵¿

Á¦7Àå ±âÁú Ç÷°ü ºÐȹ ½ÃÀå : ¿ëµµº°

  • ¼ºÇü¿Ü°ú
  • Á¤Çü¿Ü°ú
  • ¿¬ºÎ Á¶Á÷

Á¦8Àå ±âÁú Ç÷°ü ºÐȹ ½ÃÀå : ÃÖÁ¾ ¿ëµµº°

  • º´¿ø
  • Àü¹® Ŭ¸®´Ð
  • Áٱ⼼Æ÷ ÀºÇà/¿¬±¸¼Ò

Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ ±âÁú Ç÷°ü ºÐȹ ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ±âÁú Ç÷°ü ºÐȹ ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦11Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ±âÁú Ç÷°ü ºÐȹ ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦12Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸®½ºÆ®

  • Cytori Therapeutics Inc.
  • Hawaii Angels
  • Human Med AG
  • InGeneron, Inc.
  • Tissue Genesis
LSH

The Stromal Vascular Fraction Market was valued at USD 371.44 million in 2023, expected to reach USD 516.94 million in 2024, and is projected to grow at a CAGR of 39.65%, to USD 3,848.95 million by 2030.

Stromal Vascular Fraction (SVF) refers to a cluster of cells derived from adipose tissue, containing a rich assortment of regenerative cells, including mesenchymal stem cells, endothelial cells, and immune cells. The scope of SVF encompasses its significant role in regenerative medicine, aesthetics, and potentially, therapeutic applications for various diseases. The necessity of SVF springs from its capability to promote healing and tissue regeneration due to its rich cellular components. Applications are widespread, particularly in aesthetic medicine for fat grafting and tissue augmentation, orthopedics to encourage joint regeneration, and cardiology, where it has shown promise in myocardial regeneration. End-use scope primarily spans healthcare facilities, research institutes, and cosmetic surgery centers. Market growth is driven by increasing cases of chronic diseases, advancements in healthcare infrastructure, and an escalating demand for efficient, minimally invasive therapeutic solutions. Recent opportunities lie in harnessing SVF for developing treatments for neurodegenerative disorders and expanding its application across new therapeutic domains. Recommendations to leverage these opportunities include investing in research for novel SVF-based therapies, enhancing collaborations between biotech companies and healthcare providers, and focusing on regulatory compliance to ease market entry.

KEY MARKET STATISTICS
Base Year [2023] USD 371.44 million
Estimated Year [2024] USD 516.94 million
Forecast Year [2030] USD 3,848.95 million
CAGR (%) 39.65%

However, challenges persist such as regulatory hurdles due to stringent safety standards and varying compliance requirements across regions. Additionally, the market faces limitations like the high cost of SVF therapy procedures and a potential lack of awareness and understanding among healthcare providers and patients. Innovations are ripe in improving SVF extraction techniques and formulating artificial scaffold materials that enhance cell delivery and integration. Research in optimizing storage and transportation systems for SVF cells also promises business growth. The market is dynamic, characterized by rapid technological advancements and an evolving regulatory landscape, necessitating companies to stay agile and adaptable to sustain growth and innovation.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Stromal Vascular Fraction Market

The Stromal Vascular Fraction Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing research in pre-clinical and clinical investigations for regenerative medicine
    • Rising surgeries for different diseases, including osteoarthritis and cartilage regeneration
    • Growing cases of burn and skin diseases
  • Market Restraints
    • High costs of surgical devices for SVF
  • Market Opportunities
    • Technological innovations for new product launches for SVF
    • Ongoing strategic investment for the effective management of intravenous infusion
  • Market Challenges
    • Lack of skilled labor and product recalls

Porter's Five Forces: A Strategic Tool for Navigating the Stromal Vascular Fraction Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Stromal Vascular Fraction Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Stromal Vascular Fraction Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Stromal Vascular Fraction Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Stromal Vascular Fraction Market

A detailed market share analysis in the Stromal Vascular Fraction Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Stromal Vascular Fraction Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Stromal Vascular Fraction Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Stromal Vascular Fraction Market

A strategic analysis of the Stromal Vascular Fraction Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Stromal Vascular Fraction Market, highlighting leading vendors and their innovative profiles. These include Cytori Therapeutics Inc., Hawaii Angels, Human Med AG, InGeneron, Inc., and Tissue Genesis.

Market Segmentation & Coverage

This research report categorizes the Stromal Vascular Fraction Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Aspiration, Isolation, and Transfer.
  • Based on Application, market is studied across Cosmetic, Orthopedic, and Soft Tissue.
  • Based on End-Use, market is studied across Hospitals, Specialty Clinics, and Stem Cell Banks/Laboratories.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing research in pre-clinical and clinical investigations for regenerative medicine
      • 5.1.1.2. Rising surgeries for different diseases, including osteoarthritis and cartilage regeneration
      • 5.1.1.3. Growing cases of burn and skin diseases
    • 5.1.2. Restraints
      • 5.1.2.1. High costs of surgical devices for SVF
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological innovations for new product launches for SVF
      • 5.1.3.2. Ongoing strategic investment for the effective management of intravenous infusion
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of skilled labor and product recalls
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Stromal Vascular Fraction Market, by Product

  • 6.1. Introduction
  • 6.2. Aspiration
  • 6.3. Isolation
  • 6.4. Transfer

7. Stromal Vascular Fraction Market, by Application

  • 7.1. Introduction
  • 7.2. Cosmetic
  • 7.3. Orthopedic
  • 7.4. Soft Tissue

8. Stromal Vascular Fraction Market, by End-Use

  • 8.1. Introduction
  • 8.2. Hospitals
  • 8.3. Specialty Clinics
  • 8.4. Stem Cell Banks/Laboratories

9. Americas Stromal Vascular Fraction Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Stromal Vascular Fraction Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Stromal Vascular Fraction Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Cytori Therapeutics Inc.
  • 2. Hawaii Angels
  • 3. Human Med AG
  • 4. InGeneron, Inc.
  • 5. Tissue Genesis
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦